Emerging new therapeutic applications of capecitabine as a first-line chemotherapeutic agent in the management of advanced carcinomas other than colorectal carcinoma.
作者信息
Kapoor Shailendra
机构信息
Richmond, VA, USA.
出版信息
Cancer Manag Res. 2012;4:129-30. doi: 10.2147/CMAR.S31907. Epub 2012 May 8.
Abstract
摘要
相似文献
1
Emerging new therapeutic applications of capecitabine as a first-line chemotherapeutic agent in the management of advanced carcinomas other than colorectal carcinoma.卡培他滨作为一线化疗药物在除结直肠癌外的晚期癌症治疗中的新出现的治疗应用。
Cancer Manag Res. 2012;4:129-30. doi: 10.2147/CMAR.S31907. Epub 2012 May 8.
2
Randomised study of sequential versus combination chemotherapy with capecitabine, irinotecan and oxaliplatin in advanced colorectal cancer, an interim safety analysis. A Dutch Colorectal Cancer Group (DCCG) phase III study.卡培他滨、伊立替康和奥沙利铂序贯化疗与联合化疗治疗晚期结直肠癌的随机研究：一项中期安全性分析。荷兰结直肠癌研究组（DCCG）的III期研究。
Ann Oncol. 2006 Oct;17(10):1523-8. doi: 10.1093/annonc/mdl179. Epub 2006 Jul 27.
3
Evaluation of the Use of Capecitabine for the Treatment and Prevention of Actinic Keratoses, Squamous Cell Carcinoma, and Basal Cell Carcinoma: A Systematic Review.卡培他滨治疗和预防光化性角化病、鳞状细胞癌和基底细胞癌的应用评价：系统评价。
JAMA Dermatol. 2020 Oct 1;156(10):1117-1124. doi: 10.1001/jamadermatol.2020.2327.
4
Capecitabine (Xeloda) improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase III trial conducted in patients with advanced colorectal carcinoma.在一项针对晚期结直肠癌患者开展的III期试验中，与5-氟尿嘧啶加亚叶酸相比，卡培他滨（希罗达）改善了医疗资源的使用情况。
Eur J Cancer. 2001 Mar;37(5):597-604. doi: 10.1016/s0959-8049(00)00444-5.
5
Outcomes in elderly patients with advanced colorectal cancer treated with capecitabine: a population-based analysis.老年晚期结直肠癌患者接受卡培他滨治疗的结局：一项基于人群的分析。
Clin Colorectal Cancer. 2005 Nov;5(4):279-82. doi: 10.3816/ccc.2005.n.040.
6
A first case report of diffuse acneiform eruption caused by capecitabine in a patient with small-cell neuroendocrine lung carcinoma.卡培他滨引起小细胞神经内分泌肺癌患者弥漫性痤疮样皮疹的首例病例报告。
J Oncol Pharm Pract. 2016 Oct;22(5):717-9. doi: 10.1177/1078155215587542. Epub 2015 May 20.
7
Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial.卡培他滨、伊立替康和奥沙利铂序贯与联合化疗用于晚期结直肠癌（CAIRO）：一项III期随机对照试验
Lancet. 2007 Jul 14;370(9582):135-142. doi: 10.1016/S0140-6736(07)61086-1.
8
Capecitabine as salvage treatment for lymphoepithelioma-like carcinoma of lung.卡培他滨作为肺淋巴上皮瘤样癌的挽救性治疗手段。
J Thorac Oncol. 2009 Sep;4(9):1174-7. doi: 10.1097/JTO.0b013e3181b28f15.
9
Intermittent weekly high-dose capecitabine in combination with oxaliplatin: a phase I/II study in first-line treatment of patients with advanced colorectal cancer.间歇性每周高剂量卡培他滨联合奥沙利铂：一项针对晚期结直肠癌患者一线治疗的I/II期研究。
Ann Oncol. 2002 Oct;13(10):1583-9. doi: 10.1093/annonc/dkf281.
10
A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity.一项关于卡培他滨、奥沙利铂和贝伐单抗联合或不联合西妥昔单抗用于一线晚期结直肠癌的随机III期研究，即荷兰结直肠癌组（DCCG）的CAIRO2研究。毒性的中期分析。
Ann Oncol. 2008 Apr;19(4):734-8. doi: 10.1093/annonc/mdm607. Epub 2008 Feb 13.
本文引用的文献
1
Capecitabine monotherapy: review of studies in first-line HER-2-negative metastatic breast cancer.卡培他滨单药治疗：HER-2 阴性转移性乳腺癌一线治疗研究综述。
Oncologist. 2012;17(4):476-84. doi: 10.1634/theoncologist.2011-0281. Epub 2012 Mar 14.
2
Sorafenib in combination with capecitabine: an oral regimen for patients with HER2-negative locally advanced or metastatic breast cancer.索拉非尼联合卡培他滨：一种用于治疗 HER2 阴性局部晚期或转移性乳腺癌患者的口服方案。
J Clin Oncol. 2012 May 1;30(13):1484-91. doi: 10.1200/JCO.2011.36.7771. Epub 2012 Mar 12.
3
4
Capecitabine and weekly paclitaxel as first-line therapy in Thai patients with metastatic breast cancer.卡培他滨与紫杉醇周疗作为泰国转移性乳腺癌患者的一线治疗方案
Asia Pac J Clin Oncol. 2012 Mar;8(1):76-82. doi: 10.1111/j.1743-7563.2011.01467.x. Epub 2012 Jan 12.
5
[Efficacy of late accelerated hyperfractionated conformal radiotherapy combined with capecitabine for esophageal carcinoma].[卡培他滨联合晚期加速超分割适形放疗治疗食管癌的疗效]
Zhonghua Zhong Liu Za Zhi. 2011 Sep;33(9):702-6.
6
A phase II trial of fixed-dose rate gemcitabine plus capecitabine in metastatic/advanced biliary tract cancer patients.固定剂量率吉西他滨加卡培他滨治疗转移性/晚期胆道癌患者的 II 期临床试验。
Oncology. 2012;82(2):75-82. doi: 10.1159/000329079. Epub 2012 Feb 7.
7
A phase II study of capecitabine plus oxaliplatin as first-line chemotherapy in elderly patients with advanced gastric cancer.卡培他滨联合奥沙利铂作为一线化疗药物治疗老年晚期胃癌的 II 期研究。
Chemotherapy. 2012;58(1):1-7. doi: 10.1159/000335585. Epub 2012 Feb 3.
8
Evaluation of oral chemotherapy with capecitabine and cyclophosphamide plus thalidomide and prednisone in prostate cancer patients.卡培他滨和环磷酰胺联合沙利度胺和泼尼松口服化疗治疗前列腺癌患者的评价。
J Cancer Res Clin Oncol. 2012 Feb;138(2):333-9. doi: 10.1007/s00432-011-1101-2. Epub 2011 Dec 2.
9
Phase 2 study of capecitabine and irinotecan combination chemotherapy (modified XELIRI regimen) in patients with advanced gastric cancer.卡培他滨和伊立替康联合化疗（改良 XELIRI 方案）治疗晚期胃癌的Ⅱ期研究。
Am J Clin Oncol. 2011 Dec;34(6):555-60. doi: 10.1097/COC.0b013e3181f47ac1.
10
Phase II trial of capecitabine plus cisplatin as first-line therapy in patients with metastatic nasopharyngeal cancer.卡培他滨联合顺铂作为转移性鼻咽癌患者一线治疗的 II 期临床试验。
Head Neck. 2012 Sep;34(9):1225-30. doi: 10.1002/hed.21884. Epub 2011 Nov 11.
Zotero 插件